Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vbi Vaccines Inc CS (NQ: VBIV )

0.6306 -0.0080 (-1.25%)
Streaming Delayed Price Updated: 1:29 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vbi Vaccines Inc CS

< Previous 1 2 3 Next >
VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in Jefferies London Healthcare Conference
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in Upcoming Investor Conferences
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Appoints Linda Bain to Board of Directors
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19
From VBI Vaccines Inc.
Via Business Wire
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
From Brii Biosciences
Via Business Wire
VBI Vaccines to Present at Upcoming Scientific Conferences
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Results of Annual General Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in Upcoming Investor Conferences
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces $12 Million Second Tranche of Debt Financing with K2 HealthVentures
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Present Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces First Quarter 2021 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Publication of Preclinical and Challenge Study Data of its eVLP Vaccine Candidate Against COVID-19 (VBI-2902)
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in National Securities Corporation’s Biotech Investor Summit
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Presentation at the 2021 Annual Conference on Vaccinology Research
From VBI Vaccines Inc.
Via Business Wire
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
From Brii Biosciences and Vir Biotechnology, Inc. and VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate
From VBI Vaccines Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.